---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-21-000130"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2021-07-19T23:59:59+00:00"
generated_at: "2026-06-30T04:39:54.794105+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Axogen appoints John H. Johnson to board, effective July 19, 2021

## Summary
- Board increased from eight to nine members; Johnson appointed effective July 19, 2021.
- Johnson is CEO of Strongbridge Biopharma with 30+ years of biopharma experience.
- He will serve on the Governance, Nominating and Sustainability Committee and Science and Technology Committee.
- Standard director compensation: quarterly cash retainers ($10K board, $1.25K per committee) and stock option grants.
- Johnson previously held senior roles at Eli Lilly, J&J, ImClone, and Dendreon.

## SEC filing metadata
- accession: 0000805928-21-000130
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2021-07-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592821000130/0000805928-21-000130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592821000130/axgn-20210716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-21-000130
- JSON: https://secwatch.observer/filing/0000805928-21-000130.json
- Plain text: https://secwatch.observer/filing/0000805928-21-000130.txt

## Key facts
- Executive change
  John Johnson was appointed as Director at Axogen, Inc..
  - Action: appointed
  - Role: Director
  source text: On July 16, 2021, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from eight to nine members, and appointed John Johnson as a new director, effective July 19, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592821000130/0000805928-21-000130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.